UCHL3 and cancer: Since we demonstrated that farrerol binds to UCHL3 through two amino acid residues to activate its enzymatic activity, in order to treat HR-overactivated cancer or overcome radio/chemo-resistance, it is likely worthwhile to try generating farrerol derivatives that exhibit an inhibitory effect on UCHL3 while still retaining a high affinity to UCHL3.